Clinical Trials Logo

Overweight Subjects clinical trials

View clinical trials related to Overweight Subjects.

Filter by:
  • None
  • Page 1

NCT ID: NCT05815680 Completed - Overweight Subjects Clinical Trials

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Start date: April 6, 2023
Phase: Phase 1
Study type: Interventional

This trial is conducted in China. The aim of the trial is to investigate the influence of IBI362 on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of warfarin, metformin, warfarin, atorvastatin, digoxin in overweight or obese subjects.

NCT ID: NCT04782024 Completed - Clinical trials for Resting Metabolic Rate

A Study to Investigate the Effect of 7-Keto on Resting Metabolic Rate in Overweight Adults

15KMHI
Start date: September 30, 2015
Phase: Phase 2
Study type: Interventional

This study will investigate the effect of two different doses of 7-Keto compared to placebo on resting metabolic rate. One third of subjects will be given the lower 7-Keto dose, one third will be given the higher 7-Keto dose and one third will be given the placebo.

NCT ID: NCT02745886 Recruiting - Aging Clinical Trials

Metformin Induces a Dietary Restriction-like State in Human

Start date: April 2016
Phase: Phase 4
Study type: Interventional

The fact that metformin treatment has been associated with reduced risk of cancer and cardiovascular disease raises the possibility of a beneficial role of metformin for other age-related diseases. The actions of metformin resemble the effects of calorie restriction (CR) to some extent, and microarray analyses have shown that metformin induces a gene expression profile that aligns with that of CR in animal. The aim of the study is to investigate whether metformin treatment can induce dietary restriction-like state in human. Sixty overweight subjects will be included in this study, and participants will be divided 3 groups (20 cases in each group)including metformin group (0.85, twice daily), standard diet group, and CR group. All subjects will be treated 6 months. At the end of this study, blood samples and muscle samples will be obtained.